CHIlled Platelet Study "CHIPS" (CHIPS)

October 23, 2026 updated by: Philip Spinella

CHIlled Platelet Study

A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1000

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australia, 6009
        • Sir Charles Gairdner Hospital
    • Arizona
      • Pheonix, Arizona, United States, 85054
        • Mayo Clinic Arizona
      • Tuscon, Arizona, United States, 85713
        • Banner University Medical Center
    • California
      • Los Angeles, California, United States, 90095
        • Ronald Reagan UCLA Medical Center
    • Florida
      • Gainesville, Florida, United States, 32608
        • University of Florida
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern Memorial Hospital
      • Maywood, Illinois, United States, 60153
        • Loyola Universtiy Medical Center
    • Kansas
      • Kansas City, Kansas, United States, 66103
        • University of Kansas Medical Center
    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • John Hopkins
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27157
        • Wake Forest
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15232
        • University of Pittsburgh Medical Center
    • Rhode Island
      • Providence, Rhode Island, United States, 02910
        • Rhode Island Hospital
    • Texas
      • Dallas, Texas, United States, 75235
        • University of Texas Children's Medical Center
      • Dallas, Texas, United States, 75235
        • University of Texas Medical Center Clements
      • Houston, Texas, United States, 77030
        • Memorial Hermann Texas Medical Center
      • Houston, Texas, United States, 77030
        • Baylor Texas Children's
    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • University of Wisconsin- Madison
      • Milwaukee, Wisconsin, United States, 53226
        • Children's Hospital of Wisconsin
      • Milwaukee, Wisconsin, United States, 53215
        • Aurora St. Luke's Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 84 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
  • Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.

Exclusion Criteria:

  • Expected order for washed or volume reduced platelets
  • Patient with known anti-platelet antibodies
  • Platelet transfusion refractoriness due to anti-HLA antibodies
  • Known or suspected pregnancy
  • Previously randomized in this study
  • Conscious objection or unwillingness to receive blood products
  • Known IgA deficiency
  • Known congenital platelet disorder
  • Known congenital bleeding disorder
  • Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
  • Patients intended to receive whole blood either intra-operative or post-operative for bleeding
  • Platelet transfusion (of any type) within 24 hours prior to the date of surgery
  • Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Room Temperature Platelets

Platelets stored at 20-24 degrees Celsius

Platelets stored at 20-24 degrees Celsius

Experimental: Cold Stored Platelets

Platelets stored at 1-6 degree Celsius

Platelets stored at 1-6 degree Celsius

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemostatic Efficacy
Time Frame: 24 hours after first study platelet transfusion

Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.

24 hours after first study platelet transfusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chest Tube Output Through 24 Hours
Time Frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Chest tube output will be assessed by volume

24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Product Administration
Time Frame: 24 and 72 hours from start time of first study platelet transfusion

The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood

24 and 72 hours from start time of first study platelet transfusion
Transfusion Associated Adverse Events
Time Frame: within 7 days of first study platelet transfusion

As per CDC guidelines for transfusion associated adverse events

within 7 days of first study platelet transfusion
Arterial Thrombotic Event
Time Frame: within 7 days of first study platelet transfusion

Stroke, MI, aortic thromboic even

within 7 days of first study platelet transfusion
Venous Thrombotic Event
Time Frame: within 7 days of first study platelet transfusion

Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram

within 7 days of first study platelet transfusion
All Cause Mortality
Time Frame: up to 28 days

Death for any reason

up to 28 days
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Time Frame: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

Epsilon-amino-caproic acid

24 and 72 hours from start time of first study platelet transfusion
Mechanical Ventilation
Time Frame: up to 28 days after first study platelet transfusion

Number of participants with need for mechanical ventilation

up to 28 days after first study platelet transfusion
Length of Stay
Time Frame: up to 28 days

ICU and hospital length of stay

up to 28 days
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Time Frame: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Unplanned Sternal Closure Delay
Time Frame: prior to ICU admission

Sternum left open after cardiac surgery

prior to ICU admission
Re-exploration for Bleeding
Time Frame: 24 hours first study platelet transfusion

Return to OR after ICU admission

24 hours first study platelet transfusion
Unplanned Extracorporeal Support Post Operatively
Time Frame: within 48 hours of first study platelet transfusion

Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion

within 48 hours of first study platelet transfusion
Morbidities After ICU Admission
Time Frame: within 7 days of first study platelet transfusion

Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock

within 7 days of first study platelet transfusion
Measures of End Organ Injury- BUN and Creatinine
Time Frame: within 48 hours of first study platelet transfusion worst value

If BUN, creatinine are collected clinically.- worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Lactate
Time Frame: within 48 hours of first study platelet transfusion worst value

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Troponin
Time Frame: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.
Measures of End Organ Injury- ALT and AST
Time Frame: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Philip C Spinella, MD, University of Pittsburgh
  • Study Director: Marie E Steiner, MD, University of Minnesota
  • Study Director: Nicole D Zantek, MD, University of Minnesota

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 21, 2021

Primary Completion (Actual)

March 25, 2025

Study Completion (Actual)

April 21, 2025

Study Registration Dates

First Submitted

March 31, 2021

First Submitted That Met QC Criteria

April 2, 2021

First Posted (Actual)

April 8, 2021

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

October 23, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CHIPS
  • W81XWH2090021 (Other Grant/Funding Number: DoD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.